← Back to Screener
Aura Biosciences, Inc. Common Stock (AURA)
Price$7.29
Favorite Metrics
Price vs S&P 500 (26W)14.39%
Price vs S&P 500 (4W)1.80%
Market Capitalization$467.66M
All Metrics
Book Value / Share (Quarterly)$2.15
P/TBV (Annual)2.02x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.34
Price vs S&P 500 (YTD)29.62%
EPS (TTM)$-1.79
10-Day Avg Trading Volume0.36M
EPS Excl Extra (TTM)$-1.79
EPS (Annual)$-1.76
ROI (Annual)-77.56%
Cash / Share (Quarterly)$2.27
ROA (Last FY)-62.68%
EBITD / Share (TTM)$-1.85
ROE (5Y Avg)-44.35%
Cash Flow / Share (Annual)$-1.34
P/B Ratio3.42x
P/B Ratio (Quarterly)2.53x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-483.00x
ROA (TTM)-59.06%
EPS Incl Extra (Annual)$-1.76
Current Ratio (Annual)8.15x
Quick Ratio (Quarterly)7.91x
3-Month Avg Trading Volume0.24M
52-Week Price Return35.00%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.97
52-Week High$7.48
EPS Excl Extra (Annual)$-1.76
CapEx CAGR (5Y)-10.31%
26-Week Price Return23.14%
Quick Ratio (Annual)7.91x
13-Week Price Return38.59%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)8.15x
Enterprise Value$408.142
Revenue / Employee (Annual)$0
Cash / Share (Annual)$2.27
3-Month Return Std Dev57.76%
Net Income / Employee (TTM)$-1
ROE (Last FY)-77.56%
EPS Basic Excl Extra (Annual)$-1.76
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.79
ROI (TTM)-71.25%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$5.18
Price vs S&P 500 (52W)-0.09%
Year-to-Date Return33.76%
5-Day Price Return5.50%
EPS Normalized (Annual)$-1.76
ROA (5Y Avg)-37.71%
Month-to-Date Return8.97%
Cash Flow / Share (TTM)$-1.91
EBITD / Share (Annual)$-1.85
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-44.35%
EPS Basic Excl Extra (TTM)$-1.79
P/TBV (Quarterly)2.60x
P/B Ratio (Annual)2.53x
Book Value / Share (Annual)$2.15
Price vs S&P 500 (13W)35.73%
Beta0.40x
Revenue / Share (TTM)$0.00
ROE (TTM)-71.25%
52-Week Low$4.34
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.17
4.17
4.17
4.17
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
AURAAura Biosciences, Inc. Common Stock | — | — | — | — | $7.29 |
AMGNAmgen Inc | 5.21x | 9.95% | 73.30% | 2.93% | $355.30 |
GILDGilead Sciences Inc | 5.80x | 2.40% | 78.83% | 133.64% | $137.64 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $849.04 |
BNTXBioNTech SE American Depositary Share | 8.99x | -11.81% | 84.21% | — | $102.92 |
BIIBBiogen Inc. Common Stock | 2.63x | 2.22% | 75.69% | -18.77% | $177.35 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $53.72 |
NBIXNeurocrine Biosciences Inc | 4.68x | 21.45% | 98.18% | 2.31% | $133.25 |
EXELExelixis Inc | 5.02x | 6.85% | 96.39% | 31.10% | $44.89 |
TECHBio-Techne Corp. | 7.62x | 1.64% | 66.60% | -20.58% | $59.23 |
HALOHalozyme Therapeutics, Inc. | 5.88x | 37.55% | 83.62% | 22.89% | $69.29 |
About
Aura Biosciences is a clinical-stage biotechnology company developing precision immunotherapies designed to treat solid tumors while preserving organ function. Its lead candidate, bel-sar, is in late-stage clinical trials for primary choroidal melanoma and other ocular cancers, with early-stage development in bladder cancer. The company operates exclusively in the United States.